Related Experiment Video

Updated: May 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions

Jinlu Dai1, Honglai Zhang, Andreas Karatsinides

  • 1Authors' Affiliations: Departments of Urology and Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan; and Exelixis Inc., South San Francisco, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 8, 2013
PubMed
Abstract

Insights

Cabozantinib, a multityrosine kinase inhibitor, directly targets prostate cancer cells and influences bone cells. This dual action may enhance its effectiveness in treating bone metastases in castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • Castration-resistant prostate cancer (CRPC) with bone metastases presents a significant clinical challenge.
  • Cabozantinib is an orally available multityrosine kinase inhibitor targeting MET and VEGFR2.
  • Previous studies suggest cabozantinib can resolve bone scan lesions in CRPC patients.

Purpose of the Study:

  • To investigate the direct antitumor effects of cabozantinib on prostate cancer.
  • To determine if cabozantinib indirectly affects tumors by modulating bone microenvironment.
  • To elucidate the combined mechanisms underlying cabozantinib's efficacy in bone metastases.

Main Methods:

  • Prostate cancer xenograft models in mice were used to assess cabozantinib's impact on tumor growth in soft tissue and bone.
  • In vitro studies evaluated cabozantinib's effects on prostate cancer cell lines (growth, invasion, MET signaling).
  • In vitro studies examined cabozantinib's impact on osteoblast viability, differentiation, and VEGFR2 signaling.

Main Results:

  • Cabozantinib inhibited the progression of most prostate cancer cell lines in both bone and soft tissue models.
  • Direct antitumor effects included inhibition of cell viability, induction of apoptosis, and reduced invasion.
  • Cabozantinib demonstrated a dose-dependent biphasic effect on osteoblast activity and inhibited osteoclast production, impacting bone remodeling.

Conclusions:

  • Cabozantinib exhibits direct antitumor activity against prostate cancer cells.
  • Modulation of osteoblast activity by cabozantinib may contribute to its overall antitumor efficacy.
  • The findings support a dual mechanism of action for cabozantinib in treating prostate cancer bone metastases.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...